Leixir

About Leixir

Leixir Dental Laboratory Group operates as a network of full-service dental laboratories, providing a technology-enabled platform for outsourced dental solutions. The company was founded in 2013 by Harmeetpal Singh Bindra and Mangesh Sholapure, two serial entrepreneurs who previously co-founded and successfully exited a large IT services business in Southeast Asia. Their venture into the dental industry was driven by the vision to digitize a traditionally analog sector, integrating advanced technology with proven craftsmanship.

The company's business model is centered on a B2B approach, serving independent dentists, dental service organizations (DSOs), and technology and distribution firms. Leixir generates revenue by providing a comprehensive suite of dental products and services, including crowns, bridges, implants, surgical guides, dentures, and advanced ceramic systems. A key component of their offering is the InCompass system, a bundled solution that provides implants, sutures, regen materials, and final restorations at a fixed per-case cost, designed to eliminate inventory management for dental practices.

Leixir's growth strategy has involved both organic expansion and the acquisition of several dental labs across North America, integrating them into a global supply chain. The company operates six laboratories in the U.S. and a significant digital design and manufacturing facility in Gurugram, India, which is noted as one of the largest in the country. This structure allows Leixir to offer what it terms "Global Centers of Excellence," providing a wide spectrum of services. A proprietary end-to-end case management platform, MyLabConnect, is a core part of its technology offering, differentiating its service delivery. The company also emphasizes education, providing training for intraoral scanner (IOS) technology to help dental practices transition to digital workflows.

Over the years, Leixir has attracted significant investment from institutional backers, including IvyCap Ventures in 2015 and GSK Ventures in 2016. In 2021, the company was acquired by private investment firm Comvest Partners, which supported further growth initiatives. As of early 2025, global investment firm KKR was in discussions to acquire Leixir, reflecting the company's established position in the market. Harmeet Bindra, the founder, transitioned from CEO to Executive Chairman in 2022, with John Krier later appointed as CEO in 2024 to lead the company's next phase of growth.